Cited by 117Atherosclerosis and Cardiovascular DiseasesCoronary Interventions and DiagnosticsCerebrovascular and Carotid Artery Diseases

Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization

Jain, Rakesh K, Finn, Aloke V, Kolodgie, Frank D, Gold, Herman K, Virmani, Renu·2007·Nature Clinical Practice Cardiovascular Medicine

Abstract

Angiogenesis within human atherosclerotic plaques has an important role in plaque progression as immature blood vessels leak red blood cells and inflammatory mediators into the plaque center. Accumulation of free cholesterol from red blood cell membranes potentially increases the size of the necrotic core and triggers a chain of events that promote plaque destabilization. Antiangiogenic agents have been shown to prune some tumor vessels and 'normalize' the structure and function of the remaining vasculature, thereby improving the access of chemotherapeutic agents to tumors. We propose that antiangiogenic therapy can similarly stabilize vulnerable 'rupture-prone' plaques by pruning and normalizing immature intraplaque vessels, preventing further intraplaque hemorrhage. This normalization would limit necrotic core enlargement, further luminal narrowing and the degree of inflammation. Such normalization has been realized using vascular endothelial growth factor antagonists for the treatment of cancer and age-related macular degeneration. The development of this novel approach to prevent plaque progression might add to the armamentarium of preventive measures for acute myocardial infarction, stroke and sudden cardiac death.

Integrity signals

Registry

Crossref · 10.1038/ncpcardio0979

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jain, R. K., Finn, A. V., Kolodgie, F. D., Gold, H. K., & Virmani, R.
Affiliations
  • Harvard University (US)
  • CVPath Institute (US)
Corresponding author
  • Jain, Rakesh K
  • Gold, Herman K
Venue
Nature Clinical Practice Cardiovascular Medicine
Published
2007-09
Volume
4
Issue
9
Pages
491-502
ISSN
  • 1743-4297 (ISSN-L)
  • 1743-4300
OpenAlex
W2024455227
Cited by
117
References
80
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 8 · 2017: 6 · 2016: 3 · 2015: 9 · 2014: 9 · 2013: 10 · 2012: 14
FWCI
0.83
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Clinical Practice Cardiovascular Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P01CA080124)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cerebrovascular and Carotid Artery Diseases
Keywords
anti-angiogenic therapy, atherosclerotic plaque, plaque stabilization, intraplaque hemorrhage, angiogenesis, vascular normalization, vulnerable plaque, necrotic core, plaque progression, acute myocardial infarction, stroke, sudden cardiac death
MeSH terms
Coronary Artery Disease, Coronary Vessels, Hemorrhage, Humans, Neovascularization, Pathologic, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review